Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens
Author:
Funder
Open Targets
CRUK
AstraZeneca
Publisher
Elsevier BV
Subject
General Decision Sciences
Reference47 articles.
1. Towards precision medicine;Ashley;Nat. Rev. Genet.,2016
2. Evolutionary determinants of cancer;Greaves;Cancer Discov.,2015
3. A view on drug resistance in cancer;Vasan;Nature,2019
4. Biomarker development in the precision medicine era: lung cancer as a case study;Vargas;Nat. Rev. Cancer,2016
5. The NCI60 human tumour cell line anticancer drug screen;Shoemaker;Nat. Rev. Cancer,2006
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers;Science Advances;2023-11-03
2. Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020;Frontiers in Oncology;2022-09-14
3. Recent Advances and Therapeutic Strategies Using CRISPR Genome Editing Technique for the Treatment of Cancer;Molecular Biotechnology;2022-08-23
4. Biomarker LEPRE1 induces pelitinib-specific drug responsiveness by regulating ABCG2 expression and tumor transition states in human leukemia and lung cancer;Scientific Reports;2022-02-21
5. Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them;International Journal of Molecular Sciences;2021-08-31
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3